According to Cara Therapeutics 's latest financial reports the company's current earnings (TTM) are -$0.12 B. In 2022 the company made an earning of -$87.54 M an increase over its 2021 earnings that were of -$89.09 M.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$0.12 B | 34.7% |
2022 | -$87.54 M | -1.74% |
2021 | -$89.09 M | -1754.28% |
2020 | $5.38 M | -104.82% |
2019 | -$0.12 B | 44.32% |
2018 | -$77.39 M | 30.09% |
2017 | -$59.49 M | 1.86% |
2016 | -$58.4 M | 131.86% |
2015 | -$25.19 M | 39.38% |
2014 | -$18.08 M | 9120.41% |
2013 | -$0.2 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $16.97 B | -14,494.15% | ๐บ๐ธ USA |
Pfizer PFE | $3.26 B | -2,870.78% | ๐บ๐ธ USA |
Trevena TRVN | -$28.16 M | -76.12% | ๐บ๐ธ USA |
Recro Pharma
REPH | $3.76 M | -103.19% | ๐บ๐ธ USA |
Flexion Therapeutics
FLXN | -$79.39 M | -32.67% | ๐บ๐ธ USA |
Acorda Therapeutics
ACOR | $12.1 M | -110.26% | ๐บ๐ธ USA |
AcelRx Pharmaceuticals
ACRX | -$10.29 M | -91.28% | ๐บ๐ธ USA |